Jefferies Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $330

Benzinga Newsdesk www.benzinga.com Negative 89.3%

Neg 89.3% Neu 0% Pos 0%

Jefferies analyst Faisal Khurshid downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Hold and lowers the price target from $522 to $330.